Your patient Jenna is a 23-year-old woman who mentions at the end of a visit, “I recently switched from cigarettes to nicotine pouches. They’re safer, right?” She pulls a tin from her bag and tells you she keeps one in “most of the day,” especially at work where she cannot smoke. She still has a few cigarettes on weekends when stressed. She is not trying to quit nicotine altogether; she just wants something less harmful than smoking. She is looking to you for a clear answer.

Use of nicotine pouches (NPs) has expanded rapidly in the US since their introduction a decade ago. Marketed as “tobacco-free,” discreet, and usable anywhere, they are increasingly used by both former smokers and people who have never used combustible tobacco. Patients are hearing about them from peers, social media, and advertising, and clinicians are now being asked how they compare to other nicotine products. Let’s examine the answers we can provide.

What are NPs?
NPs are small white packets containing nicotine within an inert matrix. When placed between the lip and gum, the pouch slowly releases nicotine, which is absorbed through the oral mucosa. Pouches produce no smoke or vapor, and unlike traditional smokeless tobacco products, they do not require spitting.

Common NP brands include Zyn, On!, and Velo. They come in various strengths, generally between 2 mg and 9 mg per pouch, though certain high-dose forms deliver as much as 50 mg per pouch. Serum nicotine takes about 20–30 minutes to peak, which is slower than cigarettes and similar to other oral nicotine products (Travis N et al, Nicotine Tob Res 2025;27(4):598–610). Overall nicotine exposure is comparable to a nicotine lozenge, with higher-strength pouches approaching cigarette-level exposure.

Are they safe?
NPs expose users to fewer harmful chemicals than cigarettes because they do not involve combustion. However, they are not risk-free. Short-term effects include oral irritation and mucosal changes at the site of placement (Felicione NJ et al, Public Health Rep 2026;141(1):55–62). Lab analyses have found heavy metals, formaldehyde, and tobacco-specific nitrosamines in some products (Al-Otaibi HM and Althobiani MA, Front Public Health 2025;13:1641308). Long-term risks remain uncertain but likely include cardiovascular, metabolic, and oral health effects related to chronic nicotine exposure.

Patterns of use may also offset some of this potential risk reduction. Although nicotine delivery is slower with a pouch than with cigarettes, the convenience and discreet nature of pouches can promote frequent use. People typically use a pouch or two at a time for 10–30 minutes, but they can be easily replaced, with some people using them nearly continuously throughout the day (Zou H et al, J Dent 2026;166:106272). Dual use is also common, with many people smoking or vaping in certain situations while using pouches elsewhere, so pouches become a way to consume more nicotine, not less.

Keep in mind that whenever a patient switches from combustible tobacco to any smokeless nicotine product, such as pouches, they will no longer have the CYP1A2 induction caused by smoke. This could increase serum levels of drugs primarily metabolized by CYP1A2, which is important for medications with a narrow therapeutic index such as clozapine.

Who is using them and why?
Of the patients you see, young adults aged 18–40 with a history of cigarette or e-cigarette use are the most likely to be using NPs (Felicione et al, 2026). Use is rapidly increasing among adolescents as well (Han DH et al, JAMA Netw Open 2025;8(4):e256739). Many users appear to be current or former smokers who are attempting to reduce or modify their nicotine use, although pouches are also attracting people who have never smoked.

Most users choose pouches because they believe them to be safer than cigarettes (Felicione et al, 2026). The products are discreet, easy to use, and can be used in settings where smoking or vaping is not permitted, which further increases their appeal. “Tobacco-free” marketing reinforces the assumption that pouches are safe. Flavors drive initiation, especially in younger users (Zou et al, 2026).

How should you counsel patients?
Start by asking directly about nicotine use, then ask specifically about pouches, since many patients will not mention them unless prompted. A simple question such as, “What kinds of nicotine are you using, like pouches, vaping, or cigarettes?” often opens the conversation.

A useful way to respond to the assumption that NPs are safe is: “Pouches are probably less harmful than cigarettes because there is no smoke or tobacco involved, but they are not risk-free and still expose you to nicotine and other chemicals.” This keeps the message balanced and credible.

When your patient is using pouches to reduce harm, it helps to focus on actual patterns of use. You might say, “If someone switches completely from cigarettes to pouches, that likely does reduce harm. The issue is that most people end up using both, which limits that benefit.” This shifts the discussion from the product to behavior.

You should also point out the risk of escalating dependence. Many patients view pouches as a step down, but their design encourages frequent dosing. A straightforward way to frame this is: “Because you can use these anywhere, people often use them all day, which can actually make nicotine dependence stronger rather than weaker.”

If a patient’s goal is to stop nicotine entirely, the conversation should pivot to evidence-based treatment. For example: “If you want to quit, we have treatments that work better than these, like varenicline, nicotine replacement therapy, or bupropion. In contrast, pouches have not been shown to help people quit.”

Jenna is surprised to hear that pouches aren’t “basically harmless.” You explain that while they cut her exposure to combustion toxins, using them continuously through the day can deepen her nicotine dependence. The fact that she’s still smoking cigarettes on weekends means she isn’t really reducing harm, just adding a second nicotine source. She agrees to think about varenicline at her next visit.

CARLAT VERDICT
NPs likely reduce exposure to combustion toxins, but their convenience drives continuous use and higher overall nicotine intake. Ask specifically about pouch use, correct the assumption that “tobacco-free” means harmless, and steer patients who want to quit to varenicline or NRT.